Endometrial cancer: open trials in Japan

25 open trials have a site in Japan. Registry data; only the trial team decides who can take part.

NCT05579366
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Trial Treatment · Phase 1/2 · Genmab
Hyogo Cancer Center, Akashi · Fukushima Medical University Hospital, Fukushima · Saitama Medical University International Medical Center, Hidaka · Cancer Institute Hospital of JFCR, Koto · Shizuoka Cancer Center, Nagaizumi-chō · Gunma Prefectural Cancer Center, Ōta · Sapporo Medical University Hospital, Sapporo · Keio University Hospital, Shinjuku-ku · Yamagata University Hospital, Yamagata
Registry updated 2026-11-04
NCT06400472
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Trial Treatment · Phase 1 · Eli Lilly and Company
Shizuoka Cancer Center, Shizuoka · National Cancer Center Hospital, Tokyo · Cancer Institute Hospital of JFCR, Tokyo
Registry updated 2026-11-04
NCT06760819
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Trial Treatment · Phase 2 · Bayer
National Cancer Center Hospital, Chuo Ku · National Cancer Center Hospital East (NCCHE) - Kashiwa Campus, Kashiwa · The Cancer Institute Hospital of JFCR, Koto-ku · Aichi Cancer Center Hospital, Nagoya · Kindai University Hospital, Sakai · Hokkaido University Hospital, Sapporo
Registry updated 2026-11-04
NCT07166094
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Trial Treatment · Phase 3 · Genmab
Chiba University Hospital- Center for Outpatient, Chiba · National Cancer Center Hospital East, Chiba · National Hospital Organization Kyushu Cancer Center, Fukuoka · Fukushima Medical University Hospital, Fukushima · Hyogo Cancer Center, Hyōgo · Shizuoka Cancer Center, Nagaizumi-chō · Niigata Cancer Center Hospital, Niigata · Osaka International Cancer Institute - Osaka - Otemae Acti, Osaka · Gunma Prefectural Cancer Center, Ōta · Kitasato University Hospital, Sagamihara-shi · Saitama Medical University International Medical Center, Saitama · Sapporo Medical University Hospital, Sapporo · NUC Tohoku Univ. Hospital, Sendai · Iwate Medical University Hosp, Shiwa-gun · Osaka Medical and Pharmaceutical University Hospital, Takatsuki · Cancer Institute Hospital of JFCR, Tokyo · Keio University Hospital, Tokyo · Mie University Hospital, Tsu · Yamagata University Hospital, Yamagata · Kanagawa Cancer Center, Yokohama
Registry updated 2026-11-03
NCT07286331
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
Trial Treatment · Phase 3 · GlaxoSmithKline
Aichi · Fukuoka · Hokkaido · Hyōgo · Kanagawa · Kyoto · Mie · Numakunai · Okayama · Okinawa · Osaka · Saitama · Shizuoka · Tokyo
Registry updated 2026-11-03
NCT07684599
A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)
Trial Treatment · Phase 3 · GlaxoSmithKline
Fukuoka · Fukushima · Hokkaido · Ibaraki · Miyagi · Numakunai · Osaka · Saitama · Tokyo
Registry updated 2026-11-03
NCT07578649
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
Trial Treatment · Phase 3 · Pfizer
Hyogo Cancer Center, Akashi · Fukushima Medical University Hospital, Fukushima · Saitama Medical University International Medical Center, Hidaka · Cancer Institute Hospital of JFCR, Koto-Ku · Niigata Cancer Center Hospital, Niigata · Sapporo Medical University Hospital, Sapporo
Registry updated 2026-10-30
NCT07022483
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
Trial Treatment · Phase 3 · Daiichi Sankyo
Hyogo Cancer Center, Akashi-shi · National Cancer Center Hospital, Chūōku · NHO Kyushu Cancer Center, Fukuoka · Fukushima Medical University Hospital, Fukushima · Saitama Medical University International Medical Center, Hidaka-shi · Cancer Institute Hospital of JFCR, Kōtoku · Kurume University Hospital, Kurume-shi · Niigata Cancer Center Hospital, Niigata · Okayama University Hospital, Okayama · Gunma Prefectural Cancer Center, Ota-Shi · NHO Hokkaido Cancer Center, Sapporo · Tohoku University Hospital, Sendai · Keio University Hospital, Shinjuku-ku · Mie University Hospital, Tsu · Yamagata University Hospital, Yamagata
Registry updated 2026-10-27
NCT06172478
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Trial Treatment · Phase 2 · Daiichi Sankyo
Saitama Medical University International Medical Center, Hidaka · HAKUAIKAI Social Medical Corporation Sagara Hospital, Kagoshima · Kanagawa Cancer Center, Kanagawa · National Cancer Center Hospital East, Kashiwa-shi · NHO Shikoku Cancer Center, Matsuyama · Shizuoka Cancer Center, Nagaizumi-chō · Aichi Cancer Center Hospital, Nagoya · Kindai University Hospital, Osakasayama-Shi · Saitama Cancer Center, Saitama · National Cancer Center Hospital, Tokyo · Showa Medical University Hospital, Tokyo · Cancer Institute Hospital of JFCR, Tokyo · Yokohama City University Medical Center, Yokohama
Registry updated 2026-10-26
NCT06330064
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Trial Treatment · Phase 1/2 · Daiichi Sankyo
National Cancer Center Hospital, Chuo Ku · National Cancer Center Hospital East, Kashiwa · The Cancer Institute Hospital of JFCR, Koto-ku · National Hospital Organization Shikoku Cancer Center, Matsuyama · Shizuoka Cancer Center, Nagaizumi-chō · Aichi Cancer Center Hospital, Nagoya · Kindai University Hospital, Ōsaka-sayama · Saitama Cancer Center, Saitama
Registry updated 2026-10-26
NCT05123482
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Trial Treatment · Phase 1/2 · AstraZeneca
Chūōku · Hidaka-shi · Kashiwa · Kōtoku · Kurume-shi · Sunto-gun
Registry updated 2026-10-13
NCT06952504
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Hyogo Cancer Center (Site 2216), Akashi · National Cancer Center Hospital (Site 2211), Chūō · National Hospital Organization Kyushu Cancer Center (Site 2203), Fukuoka · Fukushima Medical University Hospital (Site 2218), Fukushima · Saitama Medical University International Medical Center (Site 2201), Hidaka · Cancer Institute Hospital of JFCR (Site 2208), Koto · Kurume University Hospital (Site 2204), Kurume · National Hospital Organization Shikoku Cancer Center (Site 2206), Matsuyama · Aichi Cancer Center (Site 2217), Nagoya · Niigata Cancer Center Hospital (Site 2210), Niigata · Okayama University Hospital (Site 2215), Okayama · Gunma Prefectural Cancer Center (Site 2202), Ōta · National Hospital Organization Hokkaido Cancer Center (Site 2212), Sapporo · Keio University Hospital (Site 2209), Shinjuku · Iwate Medical University Hospital (Site 2207), Shiwa-gun · Shizuoka Cancer Center (Site 2205), Sunto-gun · Ehime University Hospital (Site 2213), Tōon · Yamagata University Hospital (Site 2219), Yamagata
Registry updated 2026-10-13
NCT06989112
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Trial Treatment · Phase 3 · AstraZeneca
Akashi-shi · Ginowan-shi · Hidaka-shi · Isehara-shi · Kashiwa · Kashiwa-shi · Kobe · Kōtoku · Kurume-shi · Matsuyama · Morioka · Nagoya · Niigata · Osaka · Ota-shi · Sapporo · Sendai · Shinjuku-ku · Sunto-gun · Tokyo · Yokohama
Registry updated 2026-10-13
NCT06997029
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Trial Treatment · Phase 1 · Bristol-Myers Squibb
National Cancer Center Hospital, Chuo Ku · Kansai Medical University Hospital, Hirakata · National Cancer Center Hospital East, Kashiwa · The Cancer Institute Hospital of JFCR, Koto-ku
Registry updated 2026-10-06
NCT05797168
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Trial Treatment · Phase 1/2 · AstraZeneca
Hidaka-shi · Kashiwa · Kōtoku · Sunto-gun · Tokyo
Registry updated 2026-10-05
NCT05489211
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Trial Treatment · Phase 2 · AstraZeneca
Chūōku · Kashiwa · Kōtoku · Nagoya · Shinagawa-ku · Suita-shi
Registry updated 2026-09-23
NCT05983432
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Trial Treatment · Phase 1 · SystImmune Inc.
National Cancer Center Hospital, Chūōku
Registry updated 2026-09-21
NCT07213609
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Trial Treatment · Phase 1/2 · GlaxoSmithKline
Chiba · Osaka · Tokyo
Registry updated 2026-09-16
NCT07306559
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
Trial Treatment · Phase 1 · Boehringer Ingelheim
National Cancer Center Hospital East, Chiba, Kashiwa · Japanese Foundation for Cancer Research, Tokyo, Koto-ku
Registry updated 2026-08-21
NCT07044336
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Trial Treatment · Phase 3 · AstraZeneca
Chūōku · Hidaka-shi · Isehara-shi · Kashiwa-shi · Kōtoku · Kurume-shi · Matsuyama · Minatoku · Nagoya · Nakagami-gun · Niigata · Okayama · Osaka · Sapporo · Sendai · Suita · Sunto-gun · Toon-Shi · Tsu · Yokohama
Registry updated 2026-07-29
NCT05208762
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Trial Treatment · Phase 1 · Seagen, a wholly owned subsidiary of Pfizer
National Cancer Center Hospital East, Kashiwa · Shizuoka Cancer Center, Nagaizumi-chō
Registry updated 2026-07-22
NCT05768139
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Trial Treatment · Phase 1/2 · Eli Lilly and Company
National Hospital Organization Kyushu Cancer Center, Fukuoka · Kansai Medical University Hospital, Hirakata · The Cancer Institute Hospital of JFCR, Kōtō City · Kyoto University Hospital, Kyoto
Registry updated 2026-07-07
NCT04300556
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Trial Treatment · Phase 1/2 · Eisai Inc.
National Cancer Center Hospital, Chuo Ku · Cancer Institute Hospital of JFCR, Koto-Ku
Registry updated 2026-06-04
NCT06943521
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Trial Treatment · Phase 1/2 · Tanabe Pharma America, Inc.
National Cancer Center Hospital, Chuo Ku · National Cancer Center Hospital East, City
Registry updated 2025-12-11
NCT03438474
Endometrial Cancer Lymphadenectomy Trial
Trial Treatment · Philipps University Marburg
Okayama University Hospital, Okayama · Saitama Medical University International Medical Center, Saitama
Registry updated 2024-11-25

All Endometrial cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error